RAC1 as a Novel Therapeutic Target for Acute Liver Failure.

Autores
Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; Ciarlantini, Matías; Barquero, Andrea Alejandra; Gandolfi Donadío, Lucía; Ganiewich, Daiana; Orozco, Francisco; Fauda, Martín; Comin, Maria Julieta; Canbay, Ali; Bayo Fina, Juan Miguel; Mazzolini Rizzo, Guillermo Daniel
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.
Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; Argentina
Fil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ganiewich, Daiana. Fundación Instituto Leloir; Argentina
Fil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania
Fil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Materia
RHO GTPases
molecular inhibitors
hepatocyte apoptosis
HBV associated liver failure
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/270957

id CONICETDig_12267febf3dc3db2dc8e50d72c3534c3
oai_identifier_str oai:ri.conicet.gov.ar:11336/270957
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling RAC1 as a Novel Therapeutic Target for Acute Liver Failure.Bueloni, BárbaraFiore, Esteban JuanCantero, María JoséLameroli Mauriz, Lucia AyelenAtorrasagasti, María CatalinaCiarlantini, MatíasBarquero, Andrea AlejandraGandolfi Donadío, LucíaGaniewich, DaianaOrozco, FranciscoFauda, MartínComin, Maria JulietaCanbay, AliBayo Fina, Juan MiguelMazzolini Rizzo, Guillermo DanielRHO GTPasesmolecular inhibitorshepatocyte apoptosisHBV associated liver failurehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; ArgentinaFil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ganiewich, Daiana. Fundación Instituto Leloir; ArgentinaFil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Canbay, Ali. Ruhr Universität Bochum; AlemaniaFil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaElsevier2025-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/270957Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-432589-5559CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2589555925002265info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhepr.2025.101547info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:41:41Zoai:ri.conicet.gov.ar:11336/270957instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:41:42.154CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
title RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
spellingShingle RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
Bueloni, Bárbara
RHO GTPases
molecular inhibitors
hepatocyte apoptosis
HBV associated liver failure
title_short RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
title_full RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
title_fullStr RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
title_full_unstemmed RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
title_sort RAC1 as a Novel Therapeutic Target for Acute Liver Failure.
dc.creator.none.fl_str_mv Bueloni, Bárbara
Fiore, Esteban Juan
Cantero, María José
Lameroli Mauriz, Lucia Ayelen
Atorrasagasti, María Catalina
Ciarlantini, Matías
Barquero, Andrea Alejandra
Gandolfi Donadío, Lucía
Ganiewich, Daiana
Orozco, Francisco
Fauda, Martín
Comin, Maria Julieta
Canbay, Ali
Bayo Fina, Juan Miguel
Mazzolini Rizzo, Guillermo Daniel
author Bueloni, Bárbara
author_facet Bueloni, Bárbara
Fiore, Esteban Juan
Cantero, María José
Lameroli Mauriz, Lucia Ayelen
Atorrasagasti, María Catalina
Ciarlantini, Matías
Barquero, Andrea Alejandra
Gandolfi Donadío, Lucía
Ganiewich, Daiana
Orozco, Francisco
Fauda, Martín
Comin, Maria Julieta
Canbay, Ali
Bayo Fina, Juan Miguel
Mazzolini Rizzo, Guillermo Daniel
author_role author
author2 Fiore, Esteban Juan
Cantero, María José
Lameroli Mauriz, Lucia Ayelen
Atorrasagasti, María Catalina
Ciarlantini, Matías
Barquero, Andrea Alejandra
Gandolfi Donadío, Lucía
Ganiewich, Daiana
Orozco, Francisco
Fauda, Martín
Comin, Maria Julieta
Canbay, Ali
Bayo Fina, Juan Miguel
Mazzolini Rizzo, Guillermo Daniel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv RHO GTPases
molecular inhibitors
hepatocyte apoptosis
HBV associated liver failure
topic RHO GTPases
molecular inhibitors
hepatocyte apoptosis
HBV associated liver failure
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.
Fil: Bueloni, Bárbara. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Fiore, Esteban Juan. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Cantero, María José. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Lameroli Mauriz, Lucia Ayelen. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Ciarlantini, Matías. Instituto Nacional de Tecnología Industrial; Argentina
Fil: Barquero, Andrea Alejandra. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gandolfi Donadío, Lucía. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ganiewich, Daiana. Fundación Instituto Leloir; Argentina
Fil: Orozco, Francisco. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Fauda, Martín. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Comin, Maria Julieta. Instituto Nacional de Tecnología Industrial; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania
Fil: Bayo Fina, Juan Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
description Background & Aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 pharmacological inhibition in ALF.Methods: Ingenuity Pathway Analysis and gene ontology analysis were performed on transcriptomic datasets from ALF patients (GSE38941 and GSE80751). ALF was induced in mice using Concanavalin A, acetaminophen, or D-Galactosamine/Lipopolysaccharide (n = 10-21/group). The RAC1 pharmacological inhibitor 1D-142 was used in vivo and in vitro. Hepatocytes and macrophages, from primary cultures and cell lines, were analyzed. RNA-Seq data from ALF mouse livers (n = 3/group) were correlated with human datasets. Human liver explants (n = 6) were treated in vitro with 1D-142.Results: RAC1 emerges as an upstream regulator in human ALF samples correlating with immuneactivation and oxidative stress responses (p<0.05). Administration of 1D-142 ameliorated liver injury in murine ALF models when administered at early or late stages post-injury (p<0.05). 1D-142 treatment diminishes reactive oxygen species formation (p<0.01), inflammatory cell migration (p<0.001), cytokine production (p<0.05) and hepatocytes death (p<0.05). Liver transcriptomics revealed that RAC1 inhibition modulates key dysregulated pathways in ALF. Human ALF liver explants treated with 1D-142 showed reduced necrosis (p<0.05) and reduced expression of pro-inflammatory genes (p<0.01).Conclusions: RAC1 drives sterile inflammation and oxidative stress in ALF, and its pharmacologicalinhibition protects in murine models, supporting its potential as a therapeutic target forthis condition. Impact and implications: Acute liver failure (ALF) is a life-threatening condition with limited treatment options and is characterized by severe inflammation and oxidative stress. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF.RAC1-targeted therapy merits further studies in clinical settings.
publishDate 2025
dc.date.none.fl_str_mv 2025-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/270957
Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-43
2589-5559
CONICET Digital
CONICET
url http://hdl.handle.net/11336/270957
identifier_str_mv Bueloni, Bárbara; Fiore, Esteban Juan; Cantero, María José; Lameroli Mauriz, Lucia Ayelen; Atorrasagasti, María Catalina; et al.; RAC1 as a Novel Therapeutic Target for Acute Liver Failure.; Elsevier; JHEP Reports; 8-2025; 1-43
2589-5559
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2589555925002265
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhepr.2025.101547
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614448381165568
score 13.070432